Annual Scientific Meeting 2021
Equity and innovation in multidisciplinary lung cancer care
Virtual and OnDemand platform
It is with much pleasure that we invite you to register for the inaugural Thoracic Oncology Group of Australasia (TOGA) Annual Scientific Meeting (ASM).
While incredibly disappointing for all involved, the current COVID environment will require a switch to a virtual ASM to minimise risk to all involved.
The TOGA 2021 ASM will provide an opportunity for our multidisciplinary membership to come together to learn of advances in quality thoracic cancer care, to discuss their application in the local healthcare environment and to develop cross-cutting research capacity.
The two-day meeting program will include lung cancer screening, neoadjuvant treatment, the future influence of biomarker-driven treatments for lung cancer, the challenges of overcoming inequities in quality care, thought-provoking multi-disciplinary discussion, innovative clinical research and clinical trial concept development workshops.
Oral abstract sessions will provide an opportunity for members to present their research and a membership meeting will enable progress since TOGA was established to be outlined and invite members to engage with the TOGA leadership.
We encourage your attendance at the virtual event during 22-23 July but are also offering an OnDemand platform (with a slight delay before content can be accessed)
We acknowledge the generous support of our sponsors for the 2021 ASM. We are incredibly disappointed that we cannot meet face to face, but we are looking forward to some of the fun virtual activities that we are planning for the breaks.
Dr Emily Stone
Deputy Chair, TOGA Board of Directors,
TOGA ASM 2021 Convenor
Professor Nick Pavlakis
Chair, TOGA Board of Directors
Change to virtual meeting only
If you have already registered and paid for Face-to-Face attendance, your registration will automatically be amended to Virtual attendance and a refund of the difference in registration fees paid will be refunded via the same method that payment was originally made. A revised confirmation will be provided by email from Ozaccom+ in the coming days. Please contact Ozaccom+ on 1800 814 611 or email email@example.com with queries.
Changes to accommodation will need to be through the hotel, or if you booked through the registration platform, contact Ozaccom+
We will be in touch with speakers and chairs about changed arrangements. It is expected that you will need to do a short orientation to the virtual platform in the week leading up to the conference. Several times will be available.
There may be minor changes to the program to better accommodate the virtual program, but our content will remain the same. Please check back in a few days at the above buttons for the revised program.
Unfortunately there will be no conference dinner.
If you were awarded a travel grant, please note that these were only for eligible travel expenses as per the travel grants policy. Mostly you will be able to refund accommodation and transfer flights. Please contact TOGA on firstname.lastname@example.org if you are having issues. We may be able to recommend some travel dates for some possible TOGA events. Note that if you pay for your own flights, you are, of course, free to use the flight for personal use.
Allied health $50
Program and speakers
With a theme of Equity and Innovation in Multidisciplinary Lung Cancer Care, the program features a mix of international and local speakers drawing from all disciplines involved in the care of lung cancer patients, consumer representatives and academic researchers. Highlights include:
- Jay M Lee MD presenting on neoadjuvant options in early-stage disease
- Prof Pan-Chyr Yang presenting the TALENT study of screening in never smokers
- Prof Ramaswamy Govindan presenting on the potential of proteogenomics to identify lung cancer treatment pathways
- A/Prof Shankar Siva presenting on SABR in oligometastatic disease
- Updates in precision medicine and TOGA clinical trials led by Prof Nick Pavlakis
- A debate featuring Dr Melissa Moore and Prof Julie Brahmer presenting ‘Are two immunotherapies better than one in first line lung cancer treatment?’
- Gaps and inequities in lung cancer care, featuring health economist and Director of the Nossal Institute Prof Barbara McPake
- Immunotherapy in mesothelioma and TOGA’s DREAM3R trial presented by Prof Anna Nowak
- A session dedicated to practical tools for implementing best practice care and embedding research in lung cancer
- Multidisciplinary Masterclass
- Membership updates, oral abstracts session and TOGA scientific committee meeting
All registrants will be emailed virtual login details closer to the date of the conference. Even if you have registered for face to face attendance you will have access to the virtual platform for vital conference information.
Please see terms and conditions for further information